A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2013
At a glance
- Drugs BMS 275183 (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 29 Jun 2013 Planned number of patients 180 added as reported by European Clinical Trials Database.
- 22 Aug 2005 New trial record.